Novo Nordisk Management

Management criteria checks 3/4

Novo Nordisk's CEO is Lars Jorgensen, appointed in Jan 2017, has a tenure of 7.83 years. directly owns 0.002% of the company’s shares, worth $9.29M. The average tenure of the management team and the board of directors is 3.8 years and 6.7 years respectively.

Key information

Lars Jorgensen

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	7.8yrs
CEO ownership	0.002%
Management average tenure	3.8yrs
Board average tenure	6.7yrs

Recent management updates

No updates

Recent updates

CEO Compensation Analysis

How has Lars Jorgensen's remuneration changed compared to Novo Nordisk's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	DKK 95b
Jun 30 2024	n/a	n/a	DKK 90b
Mar 31 2024	n/a	n/a	DKK 89b
Dec 31 2023	n/a	n/a	DKK 84b
Sep 30 2023	n/a	n/a	DKK 75b
Jun 30 2023	n/a	n/a	DKK 67b
Mar 31 2023	n/a	n/a	DKK 61b
Dec 31 2022	DKK 60m	DKK 17m	DKK 56b
Sep 30 2022	n/a	n/a	DKK 53b
Jun 30 2022	n/a	n/a	DKK 51b
Mar 31 2022	n/a	n/a	DKK 49b
Dec 31 2021	DKK 58m	DKK 17m	DKK 48b
Sep 30 2021	n/a	n/a	DKK 46b
Jun 30 2021	n/a	n/a	DKK 44b
Mar 31 2021	n/a	n/a	DKK 43b
Dec 31 2020	DKK 57m	DKK 14m	DKK 42b
Sep 30 2020	n/a	n/a	DKK 42b
Jun 30 2020	n/a	n/a	DKK 41b
Mar 31 2020	n/a	n/a	DKK 40b
Dec 31 2019	DKK 55m	DKK 14m	DKK 39b
Sep 30 2019	n/a	n/a	DKK 39b
Jun 30 2019	n/a	n/a	DKK 38b
Mar 31 2019	n/a	n/a	DKK 38b
Dec 31 2018	DKK 41m	DKK 11m	DKK 39b
Sep 30 2018	n/a	n/a	DKK 38b
Jun 30 2018	n/a	n/a	DKK 39b
Mar 31 2018	n/a	n/a	DKK 39b
Dec 31 2017	DKK 32m	DKK 9m	DKK 38b

Compensation vs Market: Insufficient data to establish whether Lars's total compensation is reasonable compared to companies of similar size in the UK market.

Compensation vs Earnings: Lars's compensation has been consistent with company performance over the past year.

CEO

Lars Jorgensen (58 yo)

7.8yrs

Tenure

DKK 60,100,000

Compensation

Mr. Lars Fruergaard Jorgensen serves as Director at Danmarks Nationalbank since April 2024. He has been Chief Executive Officer and President of Novo Nordisk A/S since January 2017and serves as its Member...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Lars Jorgensen	President	7.8yrs	DKK 60.10m	0.0021% $ 9.3m
Karsten Knudsen	Executive VP	6.8yrs	DKK 21.50m	0.000010% $ 44.5k
Henrik Wulff	Executive VP of Product Supply	no data	DKK 22.00m	0.000060% $ 266.8k
Camilla Sylvest	Executive VP of Commercial Strategy & Corporate Affairs and Member of the Management Board	no data	DKK 21.30m	no data
Martin Lange	Executive VP of Development & Member of the Management Board	3.8yrs	DKK 20.90m	no data
Marcus Schindler	EVP of Research & Early Development	3.7yrs	DKK 20.90m	no data
Maziar Doustdar	Executive VP of International Operations & Member of the Management Board	no data	no data	0.0011% $ 5.0m
Douglas Langa	Executive VP of North America Operations & Member of Management Board	no data	no data	no data
Ludovic Helfgott	Executive VP	no data	no data	no data
Tania Sabroe	Executive VP of Global People & Organisation and Member of Management Board	1.7yrs	no data	no data
David Moore	Executive VP of Corporate Development & Member of Management Board	1.7yrs	no data	no data
Jacob Martin Rode	Head of Investor Relations	no data	no data	no data

3.8yrs

Average Tenure

54yo

Average Age

Experienced Management: 0TDD's management team is considered experienced (3.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Sylvie Gregoire	Independent Director	9.7yrs	DKK 1.80m	no data
Helge Lund	Independent Chairman of the Board	7.7yrs	DKK 3.10m	no data
Henrik Poulsen	Vice Chairman of the Board	3.7yrs	DKK 2.00m	no data
Laurence Debroux	Independent Director	5.7yrs	DKK 2.00m	no data
Martin MacKay	Independent Director	6.7yrs	DKK 1.70m	no data
Andreas Fibig	Independent Director	6.7yrs	DKK 1.40m	no data
Kasim Kutay	Non-Independent Director	7.7yrs	DKK 1.20m	no data
Christina Law	Independent Director	2.7yrs	DKK 1.30m	no data
Liselotte Hyveled	Employee Representative Director	2.7yrs	DKK 800.00k	0% $ 0
Mette Jensen	Employee Non-Independent Representative Director	6.7yrs	DKK 1.20m	no data
Thomas Rantzau	Employee Representative Non-Independent Director	6.8yrs	DKK 1.00m	no data
Elisabeth Christensen	Employee Representative Director	2.7yrs	DKK 800.00k	no data

6.7yrs

Average Tenure

58.5yo

Average Age

Experienced Board: 0TDD's board of directors are considered experienced (6.7 years average tenure).

Novo Nordisk Management

Management criteria checks 3/4

Key information

Recent management updates

Recent updates

Novo Nordisk A/S to Report Q2, 2025 Results on Aug 06, 2025

Novo Nordisk A/S Provides Earnings Guidance for 2024

Novo Nordisk A/S Announces Results from Part 1 of the Ongoing ESSence Trial

Novo Nordisk A/S Announces Monlunabant Phase 2A Trial in Obesity Successfully Completed

Aragen Life Sciences Reportedly Plans to Dilute About 10% Stake

Novo Nordisk A/S Decides to Pay Interim Dividend for 2024, Payable on 19 August 2024 for A and B Shares and 26 August 2024 for ADRs

European Regulatory Authority Adopts A Positive Opinion for an Update of the Wegovy® Label to Reflect Risk Reduction of Major Adverse Cardiovascular Events

Novo Nordisk Receives Complete Response Letter in the US for Once-Weekly Basal Insulin Icodec

Novo Nordisk Announces Wegovy (Semaglutide Injection) Available in Canada

Mankind Reportedly Joins Race for Healthium Medtech

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Cardior Pharmaceuticals GmbH from EQT Life Sciences and others for €1.03 billion.

Novo Nordisk Announces Awiqli Recommends for Approval for the Treatment of Diabetes by the European Regulatory Authorities

Novo Nordisk Announces US Food and Drug Administration Approves Wegovy® Based on A Supplemental New Drug Application for the Indication of Reducing Risk of Major Dose Cardiovascular Events

Novo Nordisk A/S Proposes Final Dividend for the Year 2023

Novo Nordisk A/S (CPSE:NOVO B) announces an Equity Buyback for DKK 20,000 million worth of its shares.

Novo Nordisk A/S Announces Topline Results from the Combine 3 Phase 3A Trial of Once-Weekly IcoSema

Novo Nordisk A/S to Report First Half, 2024 Results on Aug 07, 2024

Novo Nordisk Revises Earnings Guidance for the Year 2023

Novo Nordisk to Stop the Once-Weekly Injectable Semaglutide Kidney Outcomes Trial, Flow, Based on Interim Analysis

Novo Nordisk A/S (CPSE:NOVO B) acquired Embark Biotech ApS for approximately €470 million.

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire Inversago Pharma Inc. from Genesys Capital Partners Inc., Accel-Rx, Tarnagulla Ventures Pty. Ltd., Fonds de solidarité FTQ, adMare BioInnovations and others for $1 billion.

Novo Nordisk A/S Provides Earnings Guidance for the Year 2023

Novo Nordisk A/S (CPSE:NOVO B) agreed to acquire a 64.4% stake in Biocorp Production (ENXTPA:ALCOR) for €99.1 million.

Novo Nordisk Enters into Exclusive Negotiations to Acquire A Controlling Stake in Bicorp, to Be Followed by A Tender Offer on All Remaining Shares

Novo Nordisk A/S Announces Headline Results from OASIS 1

Novo Nordisk A/S to Report Fiscal Year 2023 Results on Jan 31, 2024

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age